JP2017505782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505782A5 JP2017505782A5 JP2016550703A JP2016550703A JP2017505782A5 JP 2017505782 A5 JP2017505782 A5 JP 2017505782A5 JP 2016550703 A JP2016550703 A JP 2016550703A JP 2016550703 A JP2016550703 A JP 2016550703A JP 2017505782 A5 JP2017505782 A5 JP 2017505782A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- pharmaceutical
- agents
- fgfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims 2
- 108091008101 FGF receptors Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000017175 fibroblast growth factor-activated receptor activity proteins Human genes 0.000 claims 2
- -1 salts compounds Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 1
- 206010065867 Alveolar rhabdomyosarcoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 102100013180 KDR Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 210000003205 Muscles Anatomy 0.000 claims 1
- 206010028576 Myeloproliferative disease Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000008938 Rhabdoid Tumor Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 102100011064 SELENBP1 Human genes 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 108091007928 VEGF receptors Proteins 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000000436 ligase inhibitor Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108060005085 mtoX Proteins 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 230000002071 myeloproliferative Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 201000006402 rhabdoid cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (4)
- 請求項1〜35のいずれか一項に記載の化合物及び薬剤として許容されるその塩の両方またはいずれか、及び薬剤として許容される賦形剤を含むFGFR阻害用医薬組成物。
- 任意に、少なくとも1つの他の抗癌剤と組み合わせて、請求項1〜35のいずれか一項に記載の化合物及び薬剤として許容されるその塩の両方またはいずれか、及び薬剤として許容される賦形剤を含む癌の治療用医薬組成物。
- 前記癌は乳癌、多発性骨髄腫、膀胱癌、子宮体癌、胃癌、子宮頚癌、横紋筋肉腫、肺癌、腎細胞癌、卵巣癌、食道癌、黒色腫、大腸癌、肝細胞癌、頭頸部扁平上皮細胞癌、胆管肉腫、神経膠腫、胆管癌、8,11骨髄増殖性症候群、FGFRの転座/融合を伴う骨髄増殖性疾患、胞巣状横紋筋肉腫、悪性ラブドイド腫瘍、グリア芽腫、筋層浸潤性膀胱癌、または腎癌もしくは前立腺癌である、請求項38に記載の医薬組成物。
- 前記少なくとも1つの他の抗癌剤はEGFR、MET、VEGFR、PI3K、MTO
R、MEK、プロテアソーム、またはユビキチンリガーゼ阻害剤から選択される、請求項38または39に記載の医薬組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461937211P | 2014-02-07 | 2014-02-07 | |
US61/937,211 | 2014-02-07 | ||
US201462007562P | 2014-06-04 | 2014-06-04 | |
US62/007,562 | 2014-06-04 | ||
US201462069932P | 2014-10-29 | 2014-10-29 | |
US62/069,932 | 2014-10-29 | ||
PCT/US2015/014460 WO2015120049A1 (en) | 2014-02-07 | 2015-02-04 | Quinolone derivatives as fibroblast growth factor receptor inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017505782A JP2017505782A (ja) | 2017-02-23 |
JP2017505782A5 true JP2017505782A5 (ja) | 2018-02-01 |
JP6553629B2 JP6553629B2 (ja) | 2019-07-31 |
Family
ID=52589764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016550703A Active JP6553629B2 (ja) | 2014-02-07 | 2015-02-04 | 線維芽細胞増殖因子受容体阻害剤としてのキノロン誘導体 |
Country Status (19)
Country | Link |
---|---|
US (6) | US9815834B2 (ja) |
EP (1) | EP3102577B1 (ja) |
JP (1) | JP6553629B2 (ja) |
KR (1) | KR102046448B1 (ja) |
CN (1) | CN106459034B (ja) |
AU (1) | AU2015214328B2 (ja) |
BR (1) | BR112016017137B1 (ja) |
CA (1) | CA2937746C (ja) |
CY (1) | CY1121444T1 (ja) |
DK (1) | DK3102577T3 (ja) |
ES (1) | ES2689421T3 (ja) |
HU (1) | HUE041594T2 (ja) |
IL (1) | IL246933B (ja) |
MX (1) | MX369369B (ja) |
PL (1) | PL3102577T3 (ja) |
PT (1) | PT3102577T (ja) |
RU (1) | RU2721723C2 (ja) |
SI (1) | SI3102577T1 (ja) |
WO (1) | WO2015120049A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015214328B2 (en) | 2014-02-07 | 2019-04-18 | Principia Biopharma, Inc. | Quinolone derivatives as Fibroblast Growth Factor Receptor Inhibitors |
EP3172214B1 (en) | 2014-07-26 | 2020-05-13 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Crth2拮抗劑化合物及其用途 |
US10538518B2 (en) * | 2015-08-11 | 2020-01-21 | Principia Biopharma, Inc. | Processes for preparing an FGFR inhibitor |
CN108264510A (zh) * | 2017-01-02 | 2018-07-10 | 上海喆邺生物科技有限公司 | 一种选择性抑制激酶化合物及其用途 |
WO2018153373A1 (zh) * | 2017-02-27 | 2018-08-30 | 贝达药业股份有限公司 | Fgfr抑制剂及其应用 |
JP7226804B2 (ja) * | 2017-03-03 | 2023-02-21 | オークランド ユニサービシズ リミテッド | Fgfrキナーゼ阻害剤及び医薬用途 |
CN110914267B (zh) * | 2017-07-19 | 2022-07-12 | 江苏奥赛康药业有限公司 | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 |
WO2019029541A1 (zh) * | 2017-08-08 | 2019-02-14 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂及其用途 |
CN110016026B (zh) * | 2018-01-08 | 2022-11-25 | 上海凌济生物科技有限公司 | 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途 |
AU2019338992B2 (en) * | 2018-09-14 | 2022-01-20 | Abbisko Therapeutics Co., Ltd. | FGFR inhibitor, preparation method therefor and application thereof |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
CA3136880C (en) | 2019-04-19 | 2023-09-19 | Pfizer Inc. | Anti-proliferative agents for treating pah |
US11535609B2 (en) | 2019-08-08 | 2022-12-27 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Pyrazine-2(1H)-ketone compound preparation method |
CN114901659A (zh) | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
CN115368219B (zh) * | 2022-10-25 | 2022-12-27 | 苏州康纯医药科技有限公司 | 一种fgfr抑制剂关键中间体的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US20050009849A1 (en) | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
EP1685131B1 (en) | 2003-11-13 | 2007-03-07 | F. Hoffmann-La Roche AG | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
WO2008150260A1 (en) | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
IT1395724B1 (it) | 2009-02-25 | 2012-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
KR20140105451A (ko) * | 2011-11-04 | 2014-09-01 | 아프락시스 홀딩즈 인코포레이티드 | 유약 x 증후군의 치료를 위한 pak 억제제 |
PL2872491T3 (pl) | 2012-07-11 | 2021-12-13 | Blueprint Medicines Corporation | Inhibitory receptora czynnika wzrostu fibroblastów |
WO2014182829A1 (en) | 2013-05-09 | 2014-11-13 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor inhibitors |
US9851834B2 (en) | 2013-09-10 | 2017-12-26 | Alsentis, Llc | Time domain differential techniques to characterize various stimuli |
AU2015214328B2 (en) | 2014-02-07 | 2019-04-18 | Principia Biopharma, Inc. | Quinolone derivatives as Fibroblast Growth Factor Receptor Inhibitors |
-
2015
- 2015-02-04 AU AU2015214328A patent/AU2015214328B2/en active Active
- 2015-02-04 BR BR112016017137-3A patent/BR112016017137B1/pt active IP Right Grant
- 2015-02-04 PT PT15706577T patent/PT3102577T/pt unknown
- 2015-02-04 KR KR1020167021267A patent/KR102046448B1/ko active IP Right Grant
- 2015-02-04 JP JP2016550703A patent/JP6553629B2/ja active Active
- 2015-02-04 PL PL15706577T patent/PL3102577T3/pl unknown
- 2015-02-04 US US15/022,869 patent/US9815834B2/en active Active
- 2015-02-04 MX MX2016010106A patent/MX369369B/es active IP Right Grant
- 2015-02-04 ES ES15706577.2T patent/ES2689421T3/es active Active
- 2015-02-04 WO PCT/US2015/014460 patent/WO2015120049A1/en active Application Filing
- 2015-02-04 DK DK15706577.2T patent/DK3102577T3/en active
- 2015-02-04 CN CN201580007653.5A patent/CN106459034B/zh active Active
- 2015-02-04 CA CA2937746A patent/CA2937746C/en active Active
- 2015-02-04 HU HUE15706577A patent/HUE041594T2/hu unknown
- 2015-02-04 SI SI201530358T patent/SI3102577T1/sl unknown
- 2015-02-04 EP EP15706577.2A patent/EP3102577B1/en active Active
- 2015-02-04 RU RU2016130932A patent/RU2721723C2/ru active
-
2016
- 2016-03-22 US US15/077,442 patent/US9567334B2/en active Active
- 2016-07-25 IL IL246933A patent/IL246933B/en active IP Right Grant
-
2017
- 2017-11-08 US US15/806,525 patent/US10294223B2/en active Active
-
2018
- 2018-10-18 CY CY20181101070T patent/CY1121444T1/el unknown
-
2019
- 2019-04-12 US US16/383,237 patent/US11078199B2/en active Active
-
2021
- 2021-05-03 US US17/306,528 patent/US20210292323A1/en not_active Abandoned
-
2023
- 2023-06-30 US US18/217,002 patent/US20240092777A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017505782A5 (ja) | ||
JP2017516775A5 (ja) | ||
NZ706836A (en) | Methods of treating cancer | |
HRP20210338T1 (hr) | Kombinacije fgfr-i cmet-inhibitora za liječenje raka | |
JP2016533366A5 (ja) | ||
JP2014502638A5 (ja) | ||
JP2017512791A5 (ja) | ||
JP2015512398A5 (ja) | ||
JP2017523247A5 (ja) | ||
JP2013509444A5 (ja) | ||
JP2011126896A5 (ja) | ||
JP2016528246A5 (ja) | ||
EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
JP2015536964A5 (ja) | ||
TR201819653T4 (tr) | Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik. | |
JP2015500225A5 (ja) | ||
MX2015017201A (es) | Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. | |
JP2009536652A5 (ja) | ||
JP2015502926A5 (ja) | ||
NZ628392A (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
JP2016522202A5 (ja) | ||
JP2015519396A5 (ja) | ||
JP2013520431A5 (ja) | ||
JP2019510075A5 (ja) | ||
JP2015507020A5 (ja) |